Oncosil Medical Ltd (OSL) - Total Liabilities
Based on the latest financial reports, Oncosil Medical Ltd (OSL) has total liabilities worth AU$3.29 Million AUD (≈ $2.33 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check OSL cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Oncosil Medical Ltd - Total Liabilities Trend (2005–2025)
This chart illustrates how Oncosil Medical Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see OSL total assets.
Oncosil Medical Ltd Competitors by Total Liabilities
The table below lists competitors of Oncosil Medical Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cardiex Ltd
AU:CDX
|
Australia | AU$10.39 Million |
|
NPK Co.Ltd
KQ:048830
|
Korea | ₩23.33 Billion |
|
HYUNGJI INNOVATION & CREATIVE Co.Ltd
KQ:011080
|
Korea | ₩25.13 Billion |
|
Iz Hayvancilik Tarim ve Gida Sanayi Ticaret AS
IS:IZINV
|
Turkey | TL39.95 Million |
|
Neungyule Education Inc
KQ:053290
|
Korea | ₩19.28 Billion |
|
Asuransi Jasa Tania Tbk
JK:ASJT
|
Indonesia | Rp255.97 Billion |
|
Korea Plasma Technology U Co.Ltd
KQ:054410
|
Korea | ₩39.75 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Oncosil Medical Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Oncosil Medical Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncosil Medical Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncosil Medical Ltd (2005–2025)
The table below shows the annual total liabilities of Oncosil Medical Ltd from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$4.04 Million ≈ $2.86 Million |
+104.07% |
| 2024-06-30 | AU$1.98 Million ≈ $1.40 Million |
+24.36% |
| 2023-06-30 | AU$1.59 Million ≈ $1.13 Million |
-16.41% |
| 2022-06-30 | AU$1.91 Million ≈ $1.35 Million |
-22.30% |
| 2021-06-30 | AU$2.45 Million ≈ $1.74 Million |
+13.69% |
| 2020-06-30 | AU$2.16 Million ≈ $1.53 Million |
+117.33% |
| 2019-06-30 | AU$993.21K ≈ $702.76K |
-42.51% |
| 2018-06-30 | AU$1.73 Million ≈ $1.22 Million |
+3.45% |
| 2017-06-30 | AU$1.67 Million ≈ $1.18 Million |
+53.74% |
| 2016-06-30 | AU$1.09 Million ≈ $768.63K |
+143.73% |
| 2015-06-30 | AU$445.70K ≈ $315.36K |
+269.19% |
| 2014-06-30 | AU$120.72K ≈ $85.42K |
-37.43% |
| 2013-06-30 | AU$192.95K ≈ $136.52K |
+373.07% |
| 2012-06-30 | AU$40.79K ≈ $28.86K |
-65.11% |
| 2011-06-30 | AU$116.89K ≈ $82.70K |
-69.32% |
| 2010-06-30 | AU$380.95K ≈ $269.54K |
-59.73% |
| 2009-06-30 | AU$945.93K ≈ $669.31K |
-54.52% |
| 2008-06-30 | AU$2.08 Million ≈ $1.47 Million |
-10.44% |
| 2007-06-30 | AU$2.32 Million ≈ $1.64 Million |
-14.85% |
| 2006-06-30 | AU$2.73 Million ≈ $1.93 Million |
+5699.18% |
| 2005-06-30 | AU$47.03K ≈ $33.27K |
-- |
About Oncosil Medical Ltd
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company's lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorp… Read more